NEW YORK – Foundation Medicine announced on Wednesday that it is collaborating with Science 37 to create a home-based clinical trial model for patients who can't travel to clinical trial sites.
Financial and other terms of the collaboration were not disclosed.
Under the agreement, Roche subsidiary Foundation Medicine will use its FoundationSmartTrials patient identification tool to determine which patients may be eligible for a clinical trial based on results from the company's comprehensive genomic profiling tests.
Once they've been identified, Science 37 will enroll the patients and provide ongoing support using its Science 37 Operating System, which includes a technology platform and specialized support networks of mobile nurses, telemedicine investigators, remote coordinators, and connected devices, Foundation said in a statement.
“Many advanced cancer patients are unable to travel to or visit in-person clinical trials sites, so it's critical that we work across the ecosystem towards new and innovative solutions to improve access to clinical trials regardless of a patient's location,” Jonathan Cotliar, chief medical officer at Science 37, said in a statement.
"Our goal is to improve access to clinical trials for patients who aren't frequently able to participate,” added Brian Alexander, CEO of Foundation Medicine. "As we explore this decentralized approach to research, we hope to continue innovating on this model for other clinical programs in the future. Ideally, we'll create a learning system where physicians and patients have more options, and their experiences help inform treatment for patients in the future."
Science 37 and Foundation Medicine previously collaborated to offer decentralized trial services for Roche's ALPHA-T trial, which seeks to assess the efficacy and safety of alectinib for patients with anaplastic lymphoma kinase-positive locally advanced or metastatic solid tumors excluding lung cancer.